National Centre for Healthcare Research and Pharmacoepidemiology, Laboratory of the University of Milano-Bicocca, Milan, Italy.
Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology, and Public Health, University of Milano-Bicocca, Milan, Italy.
Front Endocrinol (Lausanne). 2023 Apr 18;14:1137671. doi: 10.3389/fendo.2023.1137671. eCollection 2023.
Fragility fractures are a major public health concern owing to their worrying and growing burden and their onerous burden upon health systems. There is now a substantial body of evidence that individuals who have already suffered a fragility fracture are at a greater risk for further fractures, thus suggesting the potential for secondary prevention in this field.
This guideline aims to provide evidence-based recommendations for recognizing, stratifying the risk, treating, and managing patients with fragility fracture. This is a summary version of the full Italian guideline.
The Italian Fragility Fracture Team appointed by the Italian National Health Institute was employed from January 2020 to February 2021 to (i) identify previously published systematic reviews and guidelines on the field, (ii) formulate relevant clinical questions, (iii) systematically review literature and summarize evidence, (iv) draft the Evidence to Decision Framework, and (v) formulate recommendations.
Overall, 351 original papers were included in our systematic review to answer six clinical questions. Recommendations were categorized into issues concerning (i) frailty recognition as the cause of bone fracture, (ii) (re)fracture risk assessment, for prioritizing interventions, and (iii) treatment and management of patients experiencing fragility fractures. Six recommendations were overall developed, of which one, four, and one were of high, moderate, and low quality, respectively.
The current guidelines provide guidance to support individualized management of patients experiencing non-traumatic bone fracture to benefit from secondary prevention of (re)fracture. Although our recommendations are based on the best available evidence, questionable quality evidence is still available for some relevant clinical questions, so future research has the potential to reduce uncertainty about the effects of intervention and the reasons for doing so at a reasonable cost.
脆性骨折是一个主要的公共卫生关注点,因为它们令人担忧且不断增加的负担,以及它们给卫生系统带来的繁重负担。现在有大量证据表明,已经发生脆性骨折的个体发生进一步骨折的风险更高,因此在该领域存在潜在的二级预防。
本指南旨在为识别、分层风险、治疗和管理脆性骨折患者提供循证建议。这是意大利完整指南的摘要版本。
意大利国家卫生研究所任命的意大利脆性骨折团队于 2020 年 1 月至 2021 年 2 月(i)确定先前发表的关于该领域的系统评价和指南,(ii)制定相关临床问题,(iii)系统地审查文献并总结证据,(iv)起草证据决策框架,以及(v)制定建议。
总体而言,我们的系统评价纳入了 351 篇原始论文,以回答六个临床问题。建议分为与(i)脆性识别为骨折原因、(ii)(再)骨折风险评估有关的问题,以确定干预措施的优先级,以及(iii)脆性骨折患者的治疗和管理。总体制定了六项建议,其中一项、四项和一项分别为高质量、中质量和低质量。
目前的指南提供了指导,以支持对非创伤性骨折患者进行个体化管理,从而受益于(再)骨折的二级预防。尽管我们的建议基于现有最佳证据,但对于一些相关临床问题,仍存在质量可疑的证据,因此未来的研究有可能以合理的成本降低干预效果和进行干预的原因的不确定性。